The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

As pet owners, we always want the best for our furry companions. While we often focus on their health, diet, and daily ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Allergens like mold, pollen, and dust, if you’re sensitive to them, can inflame the throat and affect mucus production.

Are you one of these people who loathes spending time outdoors at dusk as the weather warms and mosquitoes start biting?

No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more ...

While a cocktail may be the very least appealing thing to you in the throes of a migraine attack, a "migraine cocktail" could be the very thing that helps break it. Learn what this rescue therapy ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...